You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence

    SBC: KannaLife Sciences Inc.            Topic: NIDA

    Chemotherapy induced peripheral neuropathyCIPNcan be a chronicseverely debilitating consequence of cancer therapy for which there are no effective management strategiesMoreoverupwards ofof CIPN patients reported using prescription opioids for pain management despite the fact that there is only weak evidence that long term continuation of opioids provides clinically significant pain relief in these ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Discovery of Zika virus therapeutics using a replicon assay

    SBC: MICROBIOTIX, INC.            Topic: R

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family of small positive strand RNA viruses that includes Dengue virusDENVWest Nile virusWNVYellow fever virusYFVand hepatitis C virusHCVZIKV is transmitted to humans by mosquitoes of the Aedes genusFor the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. MtLDL detection to diagnose childhood tuberculosis

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIAID

    Project SummaryChildhood TB is estimated to contributeof the disease burden in high burden settingswith approximately a million cases per year inworldwideExisting gold standard diagnostic culture tools fail to confirm TB in most childrenwho typically have low bacterial counts and cannot produce sputumMore sensitive and child friendly diagnostic tools are urgently needed to diagnose TB in childrenC ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Intravascular molecular-structural NIRF-IVUS imaging of coronary artery disease

    SBC: IntraVascular Imaging, Inc.            Topic: NHLBI

    The goal of this Phase I STTR project is to constructoptimizeand test a clinically viable intravascular near infrared fluorescence intravascular ultrasoundNIRF IVUSimaging catheter for simultaneous molecular and structural diagnosis of coronary artery diseaseCADCAD is a worldwide leading cause of death and disabilityincluding acute myocardial infarctioncongestive heart failureand sudden cardiac de ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. staRt: Enhancing speech treatment with smartphone-delivered biofeedback

    SBC: Girlfriends Labs LLC            Topic: NIDCD

    Project Summary Abstract Children with speech sound disorder show diminished accuracy and intelligibility in spoken communication and may thus be perceived as less capable or intelligent than peerseven when they are of average or above average intellectual abilityWhile most speech errors resolve by the late school age yearsup toof individuals will continue to exhibit residual speech errorsRSEthrou ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Imaging Biomarkers of Severe Respiratory Infections in Premature Infants

    SBC: KITWARE INC            Topic: NHLBI

    ABSTRACTPrematurity is the largest single cause of death in children under five in the world and lower respiratory tract infectionsLRTIare the top cause of hospitalization and mortality in premature infantsClinical tools to predict and prevent severe LRTI in premature pediatric patients are critically needed to allow early interventions to decrease the high morbidity and mortality in this patient ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Home-Based and Low-Cost ECG Device for periodic evaluation of the presence of atrial fibrillation

    SBC: Global Instrumentation, LLC            Topic: 600

    Abstract Atrial fibrillationAFprevalence is estimated toof the general population in the United StatesA shockingtoaccording to studiesof patients with AF are unaware of their diagnosissilent AFMost AF patients will suffer from congestive heart failure or and develop thromboembolic events leading to a dramatic reduction of patientsquality of lifeand a significant consumption of health care resource ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Exploration of Low-Cost Long-Timescale Free Energy Perturbations on FPGAs

    SBC: Silicon Insite, Inc.            Topic: 400

    Drug discovery is challenging and expensiveespecially in the phase of lead optimization whichpredicts binding to a targetComputational approaches can add substantial valueComputingrelative binding free energiesRBFEbetween congeneric molecules using molecular dynamicsMDgreatly reduces the search space and considerably improves convergenceThe Silicon TherapeuticsSTXINSITE platform uses an RBFE proto ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government